Candel Therapeutics Inc. Publishes Corporate Presentation Highlighting Positive Clinical Data for CAN-2409 and Pipeline Advances in Cancer Immunotherapy
Reuters
Oct 14, 2025
Candel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Publishes Corporate Presentation Highlighting Positive Clinical Data for CAN-2409 and Pipeline Advances in Cancer Immunotherapy
Candel Therapeutics Inc. has released a corporate presentation detailing progress across its clinical pipeline and financial standing. The company highlighted positive results for its lead product candidate, CAN-2409, including data from a phase 3 randomized placebo-controlled clinical trial in localized, intermediate-to-high-risk prostate cancer, as well as positive overall survival data from randomized phase 2a trials in borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. CAN-2409 has received multiple FDA designations, including Fast Track in several indications and Regenerative Medicine Advanced Therapy (RMAT) in prostate cancer. Candel's second candidate, CAN-3110, is being developed for recurrent high-grade glioma and has shown proof of concept in clinical studies. As of September 30, 2025, the company reported cash and cash equivalents of $87.2 million, with pre-commercialization activities for CAN-2409 underway. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.